Cardiomyopathy

Welcome to our featured section on cardiomyopathy

Click here to take the CME-accredited courses. 

This educational hub pulls together the latest clinical data, guidelines, congress updates as well as original video content and expert interviews on the management of cardiomyopathies. Some of the content on this hub will be CME-accredited and credits will be available when viewed on Radcliffe Medical Education – our dedicated CME portal. Instructions on how to do so are provided with individual videos. 

 

Close X
Other videos you might like

Section Advisor

Professor Perry Elliott

Chair, Cardiovascular Medicine, University College London, and Head, Clinical Research, UCL Institute of Cardiovascular Science, London, UK

Supported through an educational grant from Bristol Myers Squibb.

Recent Videos

Video

HFA 2023 Late-breaking Science Highlights

Harriette Van Spall, James L Januzzi,

Watch time: 13m 32s

Video

HFA 23: APOLLO-B: Patisiran Treatment for Cardiac Amyloidosis

Marianna Fontana,

Watch time: 3m 11s

Video

HFA 23: REDWOOD-HCM-Cohort 4: Aficamten in symptomatic nHCM

Ahmad Masri ,

Watch time: 6m 54s

Video

HFA 23 Late-breaker Discussion: The PARAGLIDE-HF Trial

Robert Mentz, Harriette Van Spall,

Watch time: 5m 48s
Entropy of left ventricular late gadolinium enhancement and its prognostic value in hypertrophic cardiomyopathy a new CMR assessment method

Zhao X, Jin F, Wang J, et al. Int J Cardiol 2023;373:134–41.

Efficacy of SGLT2 inhibitors in patients with diabetes and nonobstructive hypertrophic cardiomyopathy

Subramanian M, Sravani V, Krishna SP, et al. Am J Cardiol 2023;188:80–6.

Implications of structural right ventricular involvement in patients with hypertrophic cardiomyopathy

Zhang Y, Zhu Y, Zhang M, et al. Eur Heart J Qual Care Clin Outcomes 2023;9:34–41.

Impact of hospital volume on outcomes of septal myectomy for hypertrophic cardiomyopathy

Holst KA, Schaff HV, Smedira NG, et al. Ann Thorac Surg 2022;114:2131–8.

Detecting regional fibrosis in hypertrophic cardiomyopathy: the utility of myocardial strain based on cardiac magnetic resonance

She J, Zhao S, Chen Y, et al. Acad Radiol 2023;30:230–8.

Clinical features of heart failure in patients with hypertrophic cardiomyopathy in a regional Japanese cohort ― results from the Kochi RYOMA study ―

Miyamoto Y, Kubo T, Ochi Y, et al. Circ J 2022;86:1934–40.

Impact of race and ethnicity on use and outcomes of septal reduction therapies for obstructive hypertrophic cardiomyopathy

Patlolla SH, Schaff HV, Nishimura RA, et al. J Am Heart Assoc 2023;12:e026661.

Automated quantification of abnormal QRS peaks from high‐resolution ECGs predicts late ventricular arrhythmias in hypertrophic cardiomyopathy: a 5‐year prospective multicenter study

Suszko AM, Chakraborty P, Viswanathan K, et al. J Am Heart Assoc 2022;11:e026025.

Identification of transthyretin cardiac amyloidosis among patients previously diagnosed with hypertrophic cardiomyopathy

Rowin EJ, Ruberg FL, Das G, et al. Circ Cardiovasc Imaging 2022;15:e014938.

Is anterior mitral valve leaflet length important in outcome of septal myectomy for obstructive hypertrophic cardiomyopathy?

Lentz Carvalho J, Schaff HV, Nishimura RA, et al. J Thorac Cardiovasc Surg 2023;165:79–87.e1.

Using electronic health record data to improve understanding of the risk of mental disorders in patients diagnosed with hypertrophic cardiomyopathy

Jin K. Eur J Prev Cardiol 2023;30:82–4.

Risk of incident mental disorders in hypertrophic cardiomyopathy: a nationwide propensity-matched study

Park JB, Yun JY, Kim B, et al. Eur J Prev Cardiol 2023;30:85–94.

Effect of beta-blocker therapy on the response to mavacamten in patients with symptomatic obstructive hypertrophic cardiomyopathy

Wheeler MT, Jacoby D, Elliott PM, et al. Eur J Heart Fail 2022; epub ahead of press.

Survival after septal reduction in patients >65 years old with obstructive hypertrophic cardiomyopathy

Mentias A, Smedira NG, Krishnaswamy A, et al. J Am Coll Cardiol 2023;81:105–15.

Phase 2 study of aficamten in patients with obstructive hypertrophic cardiomyopathy

Maron MS, Masri A, Choudhury L, et al. J Am Coll Cardiol 2023;81:34–45.

Myocardial activity at (18)F-FAPI PET/CT and risk for sudden cardiac death in hypertrophic cardiomyopathy

Wang L, Wang Y, Wang J, et al. Radiology 2022; epub ahead of press.

Longitudinal cost of septal myectomy versus alcohol septal ablation for hypertrophic cardiomyopathy

Sun D, Schaff HV, Van Houten HK, et al. Mayo Clin Proc 2022;97:1656–63.

Evidence of advanced pulmonary vascular remodeling in obstructive hypertrophic cardiomyopathy with pulmonary hypertension

Maron BA, Kleiner DE, Arons E, et al. Chest 2022; epub ahead of press.

Toward ECG-based analysis of hypertrophic cardiomyopathy: a novel ECG segmentation method for handling abnormalities

Nezamabadi K, Mayfield J, Li P, et al. J Am Med Inform Assoc 2022;29:1879–89.

Magnetique: an interactive web application to explore transcriptome signatures of heart failure

Britto-Borges T, Ludt A, Boileau E, et al. J Transl Med 2022;20:513.

Posterior wall thickness associates with survival following septal myectomy for obstructive hypertrophic cardiomyopathy

Sun D, Schaff HV, Nishimura RA, et al. JACC Heart Fail 2022;10:831–7.

Validation of the Kansas City Cardiomyopathy Questionnaire in symptomatic obstructive hypertrophic cardiomyopathy

Nassif M, Fine JT, Dolan C, et al. JACC Heart Fail 2022;10:531–9.

Outcomes of patients with hypertrophic obstructive cardiomyopathy and pacemaker implanted after alcohol septal ablation

Veselka J, Liebregts M, Cooper R, et al. JACC Cardiovasc Interv 2022;15:1910–7.

Clinical characteristics and prognostic importance of left ventricular apical aneurysms in hypertrophic cardiomyopathy

Lee DZJ, Montazeri M, Bataiosu R, et al. JACC Cardiovasc Imaging 2022;15:1696–711.

Coexistent diabetes is associated with the presence of adverse phenotypic features in patients with hypertrophic cardiomyopathy

Jex N, Chowdhary A, Thirunavukarasu S, et al. Diabetes Care 2022;45:1852–62.

Multinational federated learning approach to train ECG and echocardiogram models for hypertrophic cardiomyopathy detection

Goto S, Solanki D, John JE, et al. Circulation 2022;146:755–69.

Dose-blinded myosin inhibition in patients with obstructive HCM referred for septal reduction therapy: outcomes through 32-weeks

Desai MY, Owens AT, Geske JB, et al. Circulation 2022; epub ahead of press.

Single-nucleus profiling of human dilated and hypertrophic cardiomyopathy

Chaffin M, Papangeli I, Simonson B, et al. Nature 2022;608:174–80.

The prevalence and association of exercise test abnormalities with sudden cardiac death and transplant-free survival in childhood hypertrophic cardiomyopathy

Conway J, Min S, Villa C, et al. Circulation 2022; epub ahead of press.

Natural history of MYH7-related dilated cardiomyopathy

de Frutos F, Ochoa JP, Navarro-Peñalver M, et al. J Am Coll Cardiol 2022;80:1447–61.

Association of pathogenic DNA variants predisposing to cardiomyopathy with cardiovascular disease outcomes and all-cause mortality

Patel AP, Dron JS, Wang M, et al. JAMA Cardiol 2022;7:723–32.

Rare and common genetic variation underlying the risk of hypertrophic cardiomyopathy in a national biobank

Biddinger KJ, Jurgens SJ, Maamari D, et al. JAMA Cardiol 2022;7:715–22.

High-throughput precision phenotyping of left ventricular hypertrophy with cardiovascular deep learning

Duffy G, Cheng PP, Yuan N, et al. JAMA Cardiol 2022;7:386–95.

Percutaneous intramyocardial septal radiofrequency ablation in patients with drug-refractory hypertrophic obstructive cardiomyopathy

Zhou M, Ta S, Hahn RT, et al. JAMA Cardiol 2022;7:529–38.

Muscle LIM protein force-sensing mediates sarcomeric biomechanical signaling in human familial hypertrophic cardiomyopathy

Riaz M, Park J, Sewanan LR, et al. Circulation 2022;145:1238–53.

Association of septal myectomy with quality of life in patients with left ventricular outflow tract obstruction from hypertrophic cardiomyopathy

Desai MY, Tower-Rader A, Szpakowski N, et al. JAMA Netw Open 2022;5:e227293.

Assessment of disease status and treatment response with artificial intelligence−enhanced electrocardiography in obstructive hypertrophic cardiomyopathy

Tison GH, Siontis KC, Abreau S, et al. J Am Coll Cardiol 2022;79:1032–4.

Survival following alcohol septal ablation or septal myectomy for patients with obstructive hypertrophic cardiomyopathy

Cui H, Schaff HV, Wang S, et al. J Am Coll Cardiol 2022;79:1647–55.

Clinical features and natural history of preadolescent nonsyndromic hypertrophic cardiomyopathy

Norrish G, Cleary A, Field E, et al. J Am Coll Cardiol 2022;79:1986–97.

Effects of metoprolol on exercise hemodynamics in patients with obstructive hypertrophic cardiomyopathy

Dybro AM, Rasmussen TB, Nielsen RR, et al. J Am Coll Cardiol 2022;79:1565–75.

Myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy

Desai MY, Owens A, Geske JB, et al. J Am Coll Cardiol 2022;80:95¬–108.

Impact of autophagy on prognosis of patients with dilated cardiomyopathy

Kanamori H, Yoshida A, Naruse G, et al. J Am Coll Cardiol 2022;79:789–801.

Long-term cardiovascular outcomes of COVID-19

Xie Y, Xu E, Bowe B, Al-Aly Z. Nat Med 2022;28:583–90.

Hypertensive disorders in women with peripartum cardiomyopathy: insights from the ESC EORP PPCM Registry

Jackson AM, Petrie MC, Frogoudaki A, et al. Eur J Heart Fail 2021;23:2058–69.

Phenotypic expression, natural history, and risk stratification of cardiomyopathy caused by filamin C truncating variants

Gigli M, Stolfo D, Graw SL, et al. Circulation 2021;144:1600–11.

Altered cardiac energetics and mitochondrial dysfunction in hypertrophic cardiomyopathy

Ranjbarvaziri S, Kooiker KB, Ellenberger M, et al. Circulation 2021;144:1714–31.

Association between sarcomeric variants in hypertrophic cardiomyopathy and myocardial oxygenation: insights from a novel oxygen-sensitive cardiovascular magnetic resonance approach

Raman B, Tunnicliffe EM, Chan K, et al. Circulation 2021;144:1656–8.

Effect of mavacamten on echocardiographic features in symptomatic patients with obstructive hypertrophic cardiomyopathy

Hegde SM, Lester SJ, Solomon SD, et al. J Am Coll Cardiol 2021;78:2518–32.

Randomized trial of metoprolol in patients with obstructive hypertrophic cardiomyopathy

Dybro AM, Rasmussen TB, Nielsen RR, et al. J Am Coll Cardiol 2021;78:2505–17.

Acute myocarditis following COVID-19 mRNA vaccination in adults aged 18 years or older

Simone A, Herald J, Chen A, et al. JAMA Intern Med 2021;181:1668–70.

Role of plakophilin-2 expression on exercise-related progression of arrhythmogenic right ventricular cardiomyopathy: a translational study

Cerrone M, Marrón-Liñares GM, van Opbergen CJM, et al. Eur Heart J 2022;43:1251–64.

SARS-CoV-2 vaccination and myocarditis or myopericarditis: population based cohort study

Husby A, Hansen JV, Fosbøl E, et al. BMJ 2021;375:e068665.

Myocarditis cases reported after mRNA-Based COVID-19 vaccination in the US from December 2020 to August 2021

Oster ME, Shay DK, Su JR, et al. JAMA 2022;327:331–40.

Prevalence and cumulative risk of familial idiopathic dilated cardiomyopathy

Huggins GS, Kinnamon DD, Haas GJ, et al. JAMA 2022;327:454–63.

Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection

Patone M, Mei XW, Handunnetthi L, et al. Nat Med 2022;28:410–22.

Myocarditis after BNT162b2 mRNA vaccine against covid-19 in Israel

Mevorach D, Anis E, Cedar N, et al. N Engl J Med 2021;385:2140–9.

Myocarditis after covid-19 vaccination in a large health care organization

Witberg G, Barda N, Hoss S, et al. N Engl J Med 2021;385:2132–9.

Long-term risk of sudden cardiac death in hypertrophic cardiomyopathy: a cardiac magnetic resonance outcome study

Greulich S, Seitz A, Herter D, et al. Eur Heart J Cardiovasc Imaging 2021;22:732–41.

Catheter ablation of atrial fibrillation in patients with hypertrophic cardiomyopathy: a European observational multicentre study

Creta A, Elliott P, Earley MJ, et al. Europace 2021;23:1409–17.

Echocardiographic characteristics of severe left ventricular outflow tract obstruction in hypertrophic cardiomyopathy

Jain CC, Miranda WR, Geske JB, et al. J Am Soc Echocardiogr 2021;34:798–801.

Left atrial strain and function in pediatric hypertrophic cardiomyopathy

Jhaveri S, Komarlu R, Worley S, et al. J Am Soc Echocardiogr 2021;34:996–1006.

Sleep disordered breathing and mortality in patients with hypertrophic obstructive cardiomyopathy undergoing septal myectomy

Cui H, Schaff HV, Somers VK, et al. Mayo Clin Proc 2021;96:2323–31.

Alcohol septal ablation for hypertrophic cardiomyopathy through an anomalous septal perforator off the right cusp

Mahowald MK, Corban MT, Eleid MF, Nishimura RA. JACC Cardiovasc Interv 2021;14:e129–30.

Sex-related differences in outcomes of alcohol septal ablation for hypertrophic obstructive cardiomyopathy

Veselka J, Faber L, Liebregts M, et al. JACC Cardiovasc Interv 2021;14:1390–2.

Computational prediction of protein subdomain stability in MYBPC3 enables clinical risk stratification in hypertrophic cardiomyopathy and enhances variant interpretation

Thompson AD, Helms AS, Kannan A, et al. Genet Med 2021;23:1281–7.

Association of physical activity with all-cause and cardiovascular mortality in 7666 adults with hypertrophic cardiomyopathy (HCM): more physical activity is better

Kwon S, Lee HJ, Han KD, et al. Br J Sports Med 2021;55:1034–40.

Alpha-protein kinase 3 (ALPK3) truncating variants are a cause of autosomal dominant hypertrophic cardiomyopathy

Lopes LR, Garcia-Hernández S, Lorenzini M, et al. Eur Heart J 2021;42:3063–73.

Worldwide differences in primary prevention implantable cardioverter defibrillator utilization and outcomes in hypertrophic cardiomyopathy

Nauffal V, Marstrand P, Han L, et al. Eur Heart J 2021;42:3932–44.

Myocarditis and pericarditis after vaccination for COVID-19

Diaz GA, Parsons GT, Gering SK, et al. JAMA 2021;326:1210–2.

Surveillance for adverse events after COVID-19 mRNA vaccination

Klein NP, Lewis N, Goddard K, et al. JAMA 2021;326:1390–9.

Patterns of replacement fibrosis in hypertrophic cardiomyopathy

Liu J, Zhao S, Yu S, et al. Radiology 2021; epub ahead of press.

Safety of the BNT162b2 mRNA covid-19 vaccine in a nationwide setting

Barda N, Dagan N, Ben-Shlomo Y, et al. N Engl J Med 2021;385:1078–90.

MiRNAs as biomarkers in hypertrophic cardiomyopathy: current state of the art

Angelopoulos A, Oikonomou E, Vogiatzi G, et al. Curr Med Chem 2021; epub ahead of press.

Alcohol dose in septal ablation for hypertrophic obstructive cardiomyopathy

Veselka J, Faber L, Liebregts M, et al. Int J Cardiol 2021;333:127–32.

Ablation of atrial fibrillation in patients with hypertrophic cardiomyopathy: treatment strategy, characteristics of consecutive atrial tachycardia and long‐term outcome

Dinshaw L, Münkler P, Schäffer B, et al. J Am Heart Assoc 2021;10:e017451.

Does ablation of atrial fibrillation at the time of septal myectomy improve survival of patients with obstructive hypertrophic cardiomyopathy?

Cui H, Schaff HV, Dearani JA, et al. J Thorac Cardiovasc Surg 2021;161:997–1006.e3.

Mutations in myosin S2 alter cardiac myosin-binding protein-C interaction in hypertrophic cardiomyopathy in a phosphorylation-dependent manner

Singh RR, McNamara JW, Sadayappan S. J Biol Chem 2021;297:100836.

Prevalence and clinical correlates of aortic dilation in hypertrophic cardiomyopathy

Geske JB, Nordhues BD, Orme NM, et al. J Am Soc Echocardiogr 2021;34:279–85.

Increased heart rate with sleep disordered breathing in hypertrophic cardiomyopathy

Konecny T, Khoo M, Covassin N, et al. Int J Cardiol 2021;323:155–60.

Matrix metalloproteinases increase because of hypoperfusion in obstructive hypertrophic cardiomyopathy

Bi X, Yang C, Song Y, et al. Ann Thorac Surg 2021;111:915–22.

A systematic review of microRNAs in patients with hypertrophic cardiomyopathy

Scolari FL, Faganello LS, Garbin HI, et al. Int J Cardiol 2021;327:146–54.

Dynamic thiol/disulphide homeostasis in patients with hypertrophic cardiomyopathy

Sari M, Erkorkmaz U, Yazar H, et al. Herz 2021;46:164–71.

Prognostic impact of atrial fibrillation in hypertrophic cardiomyopathy: a systematic review

Alphonse P, Virk S, Collins J, et al. Clin Res Cardiol 2021;110:544–54.

Anticoagulation for stroke prevention in patients with hypertrophic cardiomyopathy and atrial fibrillation: a review

Nasser MF, Gandhi S, Siegel RJ, Rader F. Heart Rhythm 2021;18:297–302.

Transapical septal myectomy for hypertrophic cardiomyopathy with midventricular obstruction

Sun D, Schaff HV, Nishimura RA, et al. Ann Thorac Surg 2021;111:836–44.

Arrhythmias and conduction disturbances in autoimmune rheumatic disorders

Plastiras SC, Moutsopoulos HM. Arrhythm Electrophysiol Rev 2021;10:17–25.

Coronavirus disease 2019: cardiac complications and considerations for returning to sports participation

Augustine DX, Keteepe-Arachi T, Malhotra A. Eur Cardiol 2021;16:e03.

Direct oral anticoagulants in Asian patients with atrial fibrillation: consensus recommendations by the Asian Pacific Society of Cardiology on strategies for thrombotic and bleeding risk management

Chong DTT, Andreotti F, Verhamme P, et al. Eur Cardiol 2021;16:e23.

Electrocardiographic criteria for differentiating left from right idiopathic outflow tract ventricular arrhythmias

Mariani MV, Piro A, Della Rocca DG, et al. Arrhythm Electrophysiol Rev 2021;10:10–6.

Bridging the gap in a rare cause of angina

Khadke S, Vidovic J, Patel V. Eur Cardiol 2021;16:e05.

Mavacamten favorably impacts cardiac structure in obstructive hypertrophic cardiomyopathy: EXPLORER-HCM cardiac magnetic resonance substudy analysis

Saberi S, Cardim N, Yamani M, et al. Circulation 2021;143:606–8.

Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure

Teerlink JR, Diaz R, Felker GM, et al. N Engl J Med 2021;384:105–16.

Mavacamten: treatment aspirations in hypertrophic cardiomyopathy

Papadakis M, Basu J, Sharma S. Lancet 2020;396:736–7.

Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial

Olivotto I, Oreziak A, Barriales-Villa R, et al. Lancet 2020;396:759–69.

Outcomes in patients with hypertrophic cardiomyopathy and left ventricular systolic dysfunction

Rowin EJ, Maron BJ, Carrick RT, et al. J Am Coll Cardiol 2020;75:3033–43.

Penetrance of hypertrophic cardiomyopathy in sarcomere protein mutation carriers

Lorenzini M, Norrish G, Field E, et al. J Am Coll Cardiol 2020;76:550–9.

Evaluation of mavacamten in symptomatic patients with nonobstructive hypertrophic cardiomyopathy

Ho CY, Mealiffe ME, Bach RG, et al. J Am Coll Cardiol 2020;75:2649–60.

Distinct subgroups in hypertrophic cardiomyopathy in the NHLBI HCM Registry

Neubauer S, Kolm P, Ho CY, et al. J Am Coll Cardiol 2019;74:2333–45.

Detection of hypertrophic cardiomyopathy using a convolutional neural network-enabled electrocardiogram

Ko WY, Siontis KC, Attia ZI, et al. J Am Coll Cardiol 2020;75:722–33.

Association of hypertrophic obstructive cardiomyopathy with outcomes following transcatheter aortic valve replacement

Bandyopadhyay D, Chakraborty S, Amgai B, et al. JAMA Netw Open 2020;3:e1921669.

Incidence of stress cardiomyopathy during the coronavirus disease 2019 pandemic

Jabri A, Kalra A, Kumar A, et al. JAMA Netw Open 2020;3:e2014780.

Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR‐ACT) and long‐term extension study

Damy T, Garcia-Pavia P, Hanna M, et al. Eur J Heart Fail 2020; epub ahead of press.

Biventricular pacemaker therapy improves exercise capacity in patients with non‐obstructive hypertrophic cardiomyopathy via augmented diastolic filling on exercise

Ahmed I, Loudon BL, Abozguia K, et al. Eur J Heart Fail 2020;22:1263–72.

Advanced imaging insights in apical hypertrophic cardiomyopathy

Hughes RK, Knott KD, Malcolmson J, et al. JACC Cardiovasc Imaging 2020;13:624–30.

Clinical outcomes in adult athletes with hypertrophic cardiomyopathy: a 7-year follow-up study

Pelliccia A, Caselli S, Pelliccia M, et al. Br J Sports Med 2020;54:1008–12.

Development of a novel risk prediction model for sudden cardiac death in childhood hypertrophic cardiomyopathy (HCM Risk-Kids)

Norrish G, Ding T, Field E, et al. JAMA Cardiol 2019;4:918–27.

Association of race with disease expression and clinical outcomes among patients with hypertrophic cardiomyopathy

Eberly LA, Day SM, Ashley EA, et al. JAMA Cardiol 2020;5:83–91.

Mortality among referral patients with hypertrophic cardiomyopathy vs the general European population

Lorenzini M, Anastasiou Z, O’Mahony C, et al. JAMA Cardiol 2020;5:73–80.

Association of obesity with adverse long-term outcomes in hypertrophic cardiomyopathy

Fumagalli C, Maurizi N, Day SM, et al. JAMA Cardiol 2020;5:65–72.

Undetermined stroke genesis and hidden cardiomyopathies determined by cardiac magnetic resonance

Fonseca AC, Marto JP, Pimenta D, et al. Neurology 2020;94:e107–13.

Study design and rationale of EXPLORER-HCM: evaluation of mavacamten in adults with symptomatic obstructive hypertrophic cardiomyopathy

Ho CY, Olivotto I, Jacoby D, et al. Circ Heart Fail 2020;13.

Risk stratification in cardiomyopathy

Sinagra G, Carriere C, Clemenza F, et al. Eur J Prev Cardiol 2020;27:52–8.

Access and outcomes among hypertrophic cardiomyopathy patients in a large integrated health system

Thomas A, Papoutsidakis N, Spatz E, et al. J Am Heart Assoc 2020;9.

Myocardial contraction fraction predicts mortality for patients with hypertrophic cardiomyopathy

Liao H, Wang Z, Zhao L, et al. Sci Rep 2020;10:17026.

Left ventricular global function index by magnetic resonance imaging — a novel marker for differentiating cardiac amyloidosis from hypertrophic cardiomyopathy

Huang S, Xu HY, Diao KY, et al. Sci Rep 2020;10:4707.

Implantable cardioverter defibrillators in patients with electrical heart disease and hypertrophic cardiomyopathy: data from the German device registry

Frommeyer G, Reinke F, Andresen D, et al. Clin Res Cardiol 2020;109:508–12.

Hypertrophic cardiomyopathy - a heterogeneous and lifelong disease in the real world

Kitaoka H, Kubo T, Doi YL. Circ J 2020;84:1218–26.

Comparison of expected and observed outcomes for septal myectomy in hypertrophic obstructive cardiomyopathy

Geske JB, Driver CN, Yogeswaran V, et al. Am Heart J 2020;221:159–64.

Sex-specific cardiac phenotype and clinical outcomes in patients with hypertrophic cardiomyopathy

Lu DY, Ventoulis I, Liu H, et al. Am Heart J 2020;219:58–69.

Syncope in hypertrophic cardiomyopathy (part II): an expert consensus statement on the diagnosis and management

Brignole M, Cecchi F, Anastasakis A, et al. Int J Cardiol 2022; epub ahead of press.

Perioperative implications of the 2020 American Heart Association/American College of Cardiology guidelines for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a focused review

Addis DR, Townsley MM. J Cardiothorac Vasc Anesth 2022;36:2143–53.

Prognostic relevance of a score for identifying diastolic dysfunction according to the 2016 American Society of Echocardiography/European Association of Cardiovascular Imaging recommendations in patients with hypertrophic cardiomyopathy

Saito C, Minami Y, Haruki S, et al. J Am Soc Echocardiogr 2022;35:469–76.

Recommendations for multimodality cardiovascular imaging of patients with hypertrophic cardiomyopathy

Nagueh SF, Phelan D, Abraham T, et al. J Am Soc Echocardiogr 2022;35:533–69.

Validation of the new American College of Cardiology/American Heart Association Guidelines for the risk stratification of sudden cardiac death in a large Mediterranean cohort with hypertrophic cardiomyopathy

Zegkos T, Tziomalos G, Parcharidou D, et al. Hellenic J Cardiol 2022;63:15–21.

Process of care and a practical toolkit for evaluating and managing arrhythmic risk in the cardiogenetic pregnant patient

Cheung CC, Roston TM, Davies B, et al. Can J Cardiol 2021;37:2001–13.

Comparing clinical performance of current implantable cardioverter-defibrillator implantation recommendations in arrhythmogenic right ventricular cardiomyopathy

Bosman LP, Nielsen Gerlach CL, Cadrin-Tourigny J, et al. Europace 2022;24:296–305.

2021: The American Association for Thoracic Surgery Expert Consensus Document: coronary artery bypass grafting in patients with ischemic cardiomyopathy and heart failure

Bakaeen FG, Gaudino M, Whitman G, et al. J Thorac Cardiovasc Surg 2021;162:829–50.e1.

The wait is over: the 2020 American Heart Association/American College of Cardiology (AHA/ACC) hypertrophic cardiomyopathy guidelines have arrived

Semsarian C, Davis L. Heart Lung Circ 2021;30:465–8.

Recommendations of the current guidelines for implantable cardioverter-defibrillator implantation in patients with hypertrophic cardiomyopathy: debate still exists

Aminorroaya A, Vasheghani-Farahani A, Masoudkabir F, Roayaei P. J Interv Card Electrophysiol 2021;60:1–7.

Guidelines on the verge of a more evidence-based era for hypertrophic cardiomyopathy

Ho CY. Circulation 2021;143:295–7.

2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines

Writing Committee Members, Ommen SR, Mital S, et al. J Thorac Cardiovasc Surg 2021;162:e23–106.

2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines

Writing Committee Members, Ommen SR, Mital S, et al. Circulation 2020;142:e533–57.

Clarification of the Australian heart failure guideline recommendation for primary prevention defibrillator implantation in non‐ischaemic cardiomyopathy

Kistler PM, Atherton JJ, Jennings G. Med J Aust 2020;212:509–510.e1.

Genetic testing for inherited cardiovascular diseases: a scientific statement from the American Heart Association

Musunuru K, Hershberger RE, Day SM, et al. Circ Genom Precis Med 2020;13:e000067.

Role of cardiac magnetic resonance (CMR) in planning ventricular septal myomectomy in patients with hypertrophic obstructive cardiomyopathy (HOCM)

Alenezi F, Alajmi H, Agarwal R, Zwischenberger BA. J Card Surg 2022;37:4186–9.

The uptake and utility of genetic testing and genetic counseling for hypertrophic cardiomyopathy—a systematic review and meta-analysis

Cirino AL, Harris SL, Murad AM, et al. J Genet Couns 2022;31:1290–305.

Systematic review and meta-analysis of cardiovascular consequences of myocardial bridging in hypertrophic cardiomyopathy

Bruce C, Ubhi N, McKeegan P, Sanders K. Am J Cardiol 2023;188:110–9.

Mavacamten: a novel disease-specific treatment for hypertrophic cardiomyopathy

Capilupi MJ, Frishman WH. Cardiol Rev 2023;31:45–51.

One gene, two modes of inheritance, four diseases: a systematic review of the cardiac manifestation of pathogenic variants in JPH2-encoded junctophilin-2

Parker LE, Kramer RJ, Kaplan S, Landstrom AP. Trends Cardiovasc Med 2023;33:1–10.

Comparison of demographic, clinical, biochemical, and imaging findings in hypertrophic cardiomyopathy prognosis: a network meta-analysis

Georgiopoulos G, Figliozzi S, Pateras K, et al. JACC Heart Fail 2023;11:30–41.

Mavacamten, a first-in-class cardiac myosin inhibitor for obstructive hypertrophic cardiomyopathy

Dalo JD, Weisman ND, White CM. Ann Pharmacother 2022; epub ahead of press.

Mavacamten treatment for hypertrophic cardiomyopathy: a systematic review and meta-analysis of randomized controlled trials

Ismayl M, Abbasi MA, Marar R, et al. Curr Probl Cardiol 2023;48:101429.

Is there referral bias in outcomes of septal myectomy for hypertrophic cardiomyopathy?

Calderon-Rojas R, Nguyen A, Nishimura RA, et al. J Thorac Cardiovasc Surg 2022;164:881–91.

Hypertrophic cardiomyopathy: an up-to-date snapshot of the clinical drug development pipeline

Tamargo J, Tamargo M, Caballero R. Expert Opin Investig Drugs 2022;31:1027–52.

Microvascular dysfunction in hypertrophic cardiomyopathy

Pelliccia F, Cecchi F, Olivotto I, Camici PG. J Clin Med 2022;11:6560.

The role of the submitral apparatus in hypertrophic obstructive cardiomyopathy

Tao J, Duan F, Long J, et al. J Am Soc Echocardiogr 2022; epub ahead of press.

Prevalence and clinical outcomes of transthyretin amyloidosis: a systematic review and meta-analysis

Antonopoulos AS, Panagiotopoulos I, Kouroutzoglou A, et al. Eur J Heart Fail 2022;24:1677–96.

Athletic activity for patients with hypertrophic cardiomyopathy and other inherited cardiovascular diseases: JACC Focus Seminar 3/4

Semsarian C, Gray B, Haugaa KH, et al. J Am Coll Cardiol 2022;80:1268–83.

Implantable defibrillators in primary prevention of genetic arrhythmias. A shocking choice?

Corrado D, Link MS, Schwartz PJ. Eur Heart J 2022;43:3029–40.

Latent outflow tract obstruction in hypertrophic cardiomyopathy: clinical characteristics and outcomes of septal myectomy

Cui H, Schaff HV, Nishimura RA, et al. J Thorac Cardiovasc Surg 2022;164:1863–9.e1.

Targeting the sarcomere in inherited cardiomyopathies

Lehman SJ, Crocini C, Leinwand LA. Nat Rev Cardiol 2022;19:353–63.

Mavacamten: first approval

Keam SJ. Drugs 2022;82:1127–35.

Pharmacological management of hypertrophic cardiomyopathy: from bench to bedside

Palandri C, Santini L, Argirò A, et al. Drugs 2022;82:889–912.

Long COVID: post-acute sequelae of COVID-19 with a cardiovascular focus

Raman B, Bluemke DA, Lüscher TF, Neubauer S. Eur Heart J 2022;43:1157–72.

Hypertrophic cardiomyopathy: new concepts and therapies

Maron BJ, Rowin EJ, Maron MS. Annu Rev Med 2022;73:363–75.

Inflammation and immune response in arrhythmogenic cardiomyopathy: state-of-the-art review

Asatryan B, Asimaki A, Landstrom AP, et al. Circulation 2021;144:1646–55.

Heart failure subtypes and cardiomyopathies in women

DeFilippis EM, Beale A, Martyn T, et al. Circ Res 2022;130:436–54.

The mechanism underlying extrapulmonary complications of the coronavirus disease 2019 and its therapeutic implication

Ning Q, Wu D, Wang X, et al. Signal Transduct Target Ther 2022;7:57.

Associations of race and ethnicity with presentation and outcomes of hypertrophic cardiomyopathy: JACC focus seminar 6/9

Ntusi NAB, Sliwa K. J Am Coll Cardiol 2021;78:2573–9.

Impact of racial and ethnic disparities on patients with dilated cardiomyopathy: JACC focus seminar 7/9

Ntusi NAB, Sliwa K. J Am Coll Cardiol 2021;78:2580–8.

Diagnosis and evaluation of hypertrophic cardiomyopathy: JACC state-of-the-art review

Maron BJ, Desai MY, Nishimura RA, et al. J Am Coll Cardiol 2022;79:372–89.

Management of hypertrophic cardiomyopathy: JACC state-of-the-art review

Maron BJ, Desai MY, Nishimura RA, et al. J Am Coll Cardiol 2022;79:390–414.

Echocardiographic deformation imaging for early detection of genetic cardiomyopathies: JACC review topic of the week

Taha K, Kirkels FP, Teske AJ, et al. J Am Coll Cardiol 2022;79:594–608.

Minor hypertrophic cardiomyopathy genes, major insights into the genetics of cardiomyopathies

Walsh R, Offerhaus JA, Tadros R, Bezzina CR. Nat Rev Cardiol 2022;19:151–67.

Myocarditis after COVID-19 mRNA vaccination: clinical observations and potential mechanisms

Heymans S, Cooper LT. Nat Rev Cardiol 2022;19:75–7.

Myocardial revascularization in ischaemic cardiomyopathy: routine practice vs. scientific evidence

De Caterina R, Liga R, Boden WE. Eur Heart J 2022;43:387–90.

The year in cardiovascular medicine 2021: heart failure and cardiomyopathies

Bauersachs J, de Boer RA, Lindenfeld J, Bozkurt B. Eur Heart J 2022;43:367–76.

The contribution of cardiac fatty acid oxidation to diabetic cardiomyopathy severity

Karwi QG, Sun Q, Lopaschuk GD. Cells 2021;10:3259.

Mesenchymal stem cell therapy in diabetic cardiomyopathy

da Silva JS, Gonçalves RGJ, Vasques JF, et al. Cells 2022;11:240.

Hypertrophic cardiomyopathy: a practical approach to guideline directed management

Ommen SR, Semsarian C. Lancet 2021;398:2102–8.

Cardiomyopathies: an overview

Ciarambino T, Menna G, Sansone G, Giordano M. Int J Mol Sci 2021;22:7722.

The emerging role of epigenetics in therapeutic targeting of cardiomyopathies

Pagiatakis C, Mauro VD. Int J Mol Sci 2021;22:8721.

Pathogenic mechanisms of hypertrophic cardiomyopathy beyond sarcomere dysfunction

Chou C, Chin MT. Int J Mol Sci 2021;22:8933.

Arrhythmogenic potential of myocardial disarray in hypertrophic cardiomyopathy: genetic basis, functional consequences and relation to sudden cardiac death

Finocchiaro G, Sheikh N, Leone O, et al. Europace 2021;23:985–95.

Preventative therapeutic approaches for hypertrophic cardiomyopathy

Solomon T, Filipovska A, Hool L, Viola H. J Physiol 2021;599:3495–512.

The multifaceted view of heart problem in Duchenne muscular dystrophy

Florczyk-Soluch U, Polak K, Dulak J. Cell Mol Life Sci 2021;78:5447–68.

Return to play with hypertrophic cardiomyopathy: are we moving too fast? A critical review

Drezner JA, Malhotra A, Prutkin JM, et al. Br J Sports Med 2021;55:1041–8.

Obesity cardiomyopathy: evidence, mechanisms, and therapeutic implications

Ren J, Wu NN, Wang S, et al. Physiol Rev 2021;101:1745–807.

Cardiac fibrosis and fibroblasts

Kurose H. Cells 2021;10:1716.

Genetic testing in patients with hypertrophic cardiomyopathy

Bonaventura J, Polakova E, Vejtasova V, Veselka J. Int J Mol Sci 2021;22:10401.

Update on the diagnostic pitfalls of autopsy and post-mortem genetic testing in cardiomyopathies

Grassi S, Campuzano O, Coll M, et al. Int J Mol Sci 2021;22:4124.

Emerging medical treatment for hypertrophic cardiomyopathy

Argirò A, Zampieri M, Berteotti M, et al. J Clin Med 2021;10:951.

Mavacamten, a novel therapeutic strategy for obstructive hypertrophic cardiomyopathy

Zampieri M, Argirò A, Marchi A, et al. Curr Cardiol Rep 2021;23:79.

Catheter Management Of Hypertrophic Cardiomyopathy

Dahal R, Siddiqui T, Adnan G. Catheter Management Of Hypertrophic Cardiomyopathy. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan–. 2021 May 2.

Differential diagnosis of apical hypertrophic cardiomyopathy and apical displacement of the papillary muscles: a multimodality imaging point of view

Ünlü S, Özden Tok Ö, Avcı Demir F, et al. Echocardiography 2021;38:103–13.

The role of mitral valve in hypertrophic obstructive cardiomyopathy: an updated review

Sakellaropoulos S, Svab S, Mohammed M, et al. Curr Probl Cardiol 2021;46:100641.

Coronary microvascular dysfunction in hypertrophic cardiomyopathy: pathophysiology, assessment, and clinical impact

Aguiar Rosa S, Rocha Lopes L, Fiarresga A, et al. Microcirculation 2021;28:e12656.

Mitral valve in hypertrophic cardiomyopathy: a three-dimensional transesophageal study

Venieri E, Aggeli C, Anastasakis A, et al. Hellenic J Cardiol 2021;62:29–34.

The regulatory roles of p53 in cardiovascular health and disease

Men H, Cai H, Cheng Q, et al. Cell Mol Life Sci 2021;78:2001–18.

Disopyramide

Sundjaja JH, Makaryus AN. Disopyramide. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan–. 2021 May 28.

Cardiovascular genetics: the role of genetic testing in diagnosis and management of patients with hypertrophic cardiomyopathy

Ahluwalia M, Ho CY. Heart 2021;107:183–9.

Targeting the population for gene therapy with MYBPC3

Carrier L. J Mol Cell Cardiol 2021;150:101–8.

Calcium Channel Blockers

McKeever RG, Hamilton RJ. Calcium Channel Blockers. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan–. 2020 Jul 10.

Hypertrophic cardiomyopathy in pregnancy

Saberi S. Cardiol Clin 2021;39:143–50.

Epidemiology of the inherited cardiomyopathies

McKenna WJ, Judge DP. Nat Rev Cardiol 2021;18:22–36.

Hypertrophic Cardiomyopathy

Basit H, Brito D, Sharma S. Hypertrophic Cardiomyopathy. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan–. 2021 Jul 11.

Hypertrophic Cardiomyopathy Overview

Cirino AL, Ho C. Hypertrophic Cardiomyopathy Overview. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Mirzaa G, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2021. 2008 [updated 2021].

Efficacy of echocardiography for differential diagnosis of left ventricular hypertrophy: special focus on speckle-tracking longitudinal strain

Tanaka H. J Echocardiogr 2021;19:71–9.

Risk of chronic cardiomyopathy among patients with the acute phase or indeterminate form of Chagas disease: a systematic review and meta-analysis

Chadalawada S, Sillau S, Archuleta S, et al. JAMA Netw Open 2020;3:e2015072.

Contemporary application of cardiovascular magnetic resonance imaging

Han Y, Chen Y, Ferrari VA. Annu Rev Med 2020;71:221–34.

Epsilon waves in biventricular arrythmogenic cardiomyopathy

Lezcano Gort LE, Kounka Z, Roque Rodríguez B. Ann Emerg Med 2020;76:583–5.

Hypertrophic cardiomyopathy: is a 'cure' coming . . . or is it already here?

Maron BJ, Rowin EJ, Maron MS. Am J Med 2020;133:886–8.

Pharmacotherapy for the treatment of obstructive hypertrophic cardiomyopathy

Spoladore R, Fragasso G, Pannone L, et al. Expert Opin Pharmacother 2020;21:233–42.

Prognostic value of myocardial fibrosis on cardiac magnetic resonance imaging in patients with ischemic cardiomyopathy: a systematic review

Chery G, Kamp N, Kosinski AS, et al. Am Heart J 2020;229:52–60.

Arrhythmogenic Cardiomyopathy: A Disease or Merely a Phenotype?

European Cardiology Review 2020;15:e11.

Clinical Features and Outcomes of Patients with Chemotherapy-induced Takotsubo Syndrome

US Cardiology Review 2019;13(2):74–82.

Hypertrophic Cardiomyopathy in Athletes

European Cardiology Review 2017;12(2):80–2

Atrial Fibrillation and Anticoagulation in Hypertrophic Cardiomyopathy

Arrhythmia & Electrophysiology Review 2017;6(2):63–8.

Role of T1 Mapping in Inherited Cardiomyopathies

European Cardiology Review 2016;11(2):96–101

Subclinical Atrial Fibrillation in Patients with Hypertrophic Cardiomyopathy

US Cardiology Review 2016;10(2):75–7

Arrhythmogenic Cardiomyopathy: Electrical and Structural Phenotypes

Arrhythmia & Electrophysiology Review 2016;5(2):90–101

ICD Therapy for Primary Prevention in Hypertrophic Cardiomyopathy

Arrhythmia & Electrophysiology Review 2016;5(3):188–96

The Role of Cardiac MRI in the Diagnosis and Risk Stratification of Hypertrophic Cardiomyopathy

Arrhythmia & Electrophysiology Review 2016;5(3):197–202

Risk Stratification in Hypertrophic Cardiomyopathy

European Cardiology Review 2015;10(1):31–6

Mimics of Hypertrophic Cardiomyopathy - Diagnostic Clues to Aid Early Identification of Phenocopies

Arrhythmia & Electrophysiology Review 2013;2(1):36-40

Troponin in Non-ischaemic Dilated Cardiomyopathy

European Cardiology 2011;7(3):220–4

Diagnosis and Management of Cardiomyopathies - A Focus on Genetics, Cardiac Magnetic Resonance and Clinical Features

European Cardiology 2011;7(3):225–9

Histopathological Changes and Clinical Implications in Patients with Hypertrophic Cardiomyopathy

European Cardiology 2010;6(2):88–90

Left Ventricular Non-compaction Cardiomyopathy

American Heart Hospital Journal 2010;8(2):122–4

Myocardial Perfusion Imaging in Hypertrophic Cardiomyopathy

American Heart Hospital Journal 2010;8(2):103–4

Inherited Channelopathies and Cardiomyopathies - When Is Invasive Risk Stratification Needed?

Asia-Pacific Cardiology 2011;3(1):64-6

Alcohol Septal Ablation for Obstructive Hypertrophic Cardiomyopathy

European Cardiovascular Disease 2007;3(2):88–91

Hypertrophic cardiomyopathy as an unexpected mimic of inducible laryngeal obstruction: the case for cardiopulmonary exercise testing in otolaryngology

Wertheim BM, Kapur S, Lakdawala NK, Carroll TL. J Voice 2023;37:97–100.

Effective treatment of hypertrophic cardiomyopathy with left ventricular outflow tract obstruction using a covered stent

Pekas D, Chawda A, Desai N. BMJ Case Rep 2022;15:e250929.

Hypertrophic cardiomyopathy and left ventricular non-compaction cardiomyopathy: two in one

Gabra B, Anavekar NS, Haaf P. Eur Heart J 2023;44:327.

Concerns with patient reported outcome measurement and value claims for therapy response: the case of mavacamten and symptomatic hypertrophic cardiomyopathy (SHCM)

Langley PC. Innov Pharm 2022;13:10.24926/iip.v13i2.4861.

Hypertrophic cardiomyopathy with extreme outflow tract obstruction

Geske JB, Stephens EH, Dearani JA. Eur Heart J 2022;43:4518.

Multimodality imaging of LEOPARD syndrome: myocardial hypertrophy with diffuse coronary artery dilation

Yang D, Wang Y, Lu M. JACC Case Rep 2022;4:1042–8.

Transcatheter mitral intervention relieves dynamic outflow obstruction and reduces cardiac workload in hypertrophic cardiomyopathy

Kimmelstiel C, Everett KD, Jain P, et al. Circ Heart Fail 2022;15:e009171.

Complete resolution of apical hypertrophy and fibrosis: the role of serial cardiovascular magnetic resonance tissue characterization to differentiate hypertrophic cardiomyopathy from myocarditis

Wilson J, Muthumala A, Khanji MY. Eur Heart J 2022;43:1774.

Multimodality imaging and histopathology in a young man presenting with fulminant lymphocytic myocarditis and cardiogenic shock after mRNA-1273 vaccination

Kadwalwala M, Chadha B, Ortoleva J, Joyce M. BMJ Case Rep 2021;14:e246059.

Mutation of the MYL3 gene in a patient with mid-ventricular obstructive hypertrophic cardiomyopathy

Mavilakandy A, Ahamed H. BMJ Case Rep 2022;15:e244573.

Acute-onset heart failure secondary to biventricular non-compaction cardiomyopathy and atrial septal defect in a woman presenting in the seventh decade

Sharma P, Jobanputra Y, Chait R, Ghumman W. BMJ Case Rep 2022;15:e246385.

Clinically suspected myocarditis temporally related to COVID-19 vaccination in adolescents and young adults: suspected myocarditis after COVID-19 vaccination

Truong DT, Dionne A, Muniz JC, et al. Circulation 2022;145:345–56.

A pacemaker red herring and a hypertrophic cardiomyopathy copycat

Raber I, Palmeri NO, Tahir UA, Zimetbaum PJ. Circulation 2022;145:622–5.

Carditis after COVID-19 vaccination with a messenger RNA vaccine and an inactivated virus vaccine : a case–control study

Lai FTT, Li X, Peng K, et al. Ann Intern Med 2022;175:362–70.

'Heart within a heart': echocardiographic assessment of hypertrophic cardiomyopathy

Weerasekare JM, Geske JB. Eur Heart J 2021;42:4775.

Hydroxychloroquine-induced cardiomyopathy accelerated after gastric banding

Lodge FM, Moody WE, Tosounidou S, et al. Lancet 2021;398:1913.

Rare presentation of Fabry disease as 'burnt-out' hypertrophic cardiomyopathy

Williams S, El-Medany A, Nightingale A, Ismail Y. BMJ Case Rep 2021;14:e243604.

Anderson–Fabry disease: a rare phenocopy of hypertrophic cardiomyopathy

Yang K, Wei MD, Chen XY, Zhao SH. Eur Heart J Cardiovasc Imaging 2021;22:e94.

Myocarditis after covid-19 mRNA vaccination

Verma AK, Lavine KJ, Lin CY. N Engl J Med 2021;385:1332–4.

Myocarditis combined with hypertrophic cardiomyopathy: a case report

Wang JY, Wang YS, Shen BT. Ann Palliat Med 2021; epub ahead of press.

A special case of hypertrophic cardiomyopathy with a differential diagnosis of isolated cardiac amyloidosis or junctophilin type 2 associated cardiomyopathy

De Bruijn S, Galloo X, De Keulenaer G, et al. Acta Clin Belg 2021;76:136–43.

Nonobstructive hypertrophic cardiomyopathy in a patient with mitral prosthesis

Sun D, Schaff HV, Gersh BJ, Borlaug BA. Ann Thorac Surg 2021;111:e429–32.

Management and outcome of hypertrophic obstructive cardiomyopathy in pregnant women: a case report

Assamti M, Bougrine R, Ismaili N, Ouafi NE. Pan Afr Med J 2021;38:140.

Syncope in hypertrophic cardiomyopathy: explaining the unexplained

Geske JB, Siontis KC, Gersh BJ. Int J Cardiol 2023;373:99–100.

High‐resolution ECG for predicting ventricular arrhythmia in hypertrophic cardiomyopathy: another tool in the toolbox

Gehi AK. J Am Heart Assoc 2022;11:e028095.

Composite endpoints in hypertrophic cardiomyopathy: practice, education, research

Ommen SR. JACC Heart Fail 2023;11:42–3.

Mavacamten in obstructive hypertrophic cardiomyopathy – are beta-blockers blocking part of its shine?

Dominguez F, Cabrera E. Eur J Heart Fail 2023; epub ahead of press.

Increased long-term survival after myectomy: is the pendulum swinging again in this 30-year debate?

Maron MS. J Am Coll Cardiol 2023;81:116–8.

Myosin inhibitors: the next generation

Nair A, Xie L, Silva Enciso JE. J Am Coll Cardiol 2023;81:46–8.

Commentary: invasive therapy for hypertrophic obstructive cardiomyopathy: is it time to reexamine the guidelines?

Mazine A, Tam DY, Fremes SE. J Thorac Cardiovasc Surg 2022;164:1511–3.

Commentary: septal reduction therapy: the sooner, the better?

Wei LM. J Thorac Cardiovasc Surg 2022;164:1513–4.

Evolving epidemiology of hypertrophic cardiomyopathy: shifting the focus from instant to lifetime risk awareness

Canepa M, Olivotto I. Circ Heart Fail 2022;15:e009873.

Refining endpoint measures in clinical trials for hypertrophic cardiomyopathy: the emerging role of patient-reported outcomes

Rowin EJ, Maron MS. JACC Heart Fail 2022;10:540–2.

Left ventricular posterior wall in obstructive hypertrophic cardiomyopathy: a neglected issue in clinical management?

de Gregorio C, Luongo A. JACC Heart Fail 2022;10:838–41.

New pacemaker implantation after alcohol septal ablation: how sharp is the double-edged sword?

Pineda AM, Wang A. JACC Cardiovasc Interv 2022;15:1918–20.

Understanding the prognostic significance of left ventricular apical aneurysms in hypertrophic cardiomyopathy

Elliott PM, Lorenzini M. JACC Cardiovasc Imaging 2022;15:1712–4.

Myosin-related dilated cardiomyopathy: another elephant emerges from darkness

Lanfear DE, Reza N. J Am Coll Cardiol 2022;80:1462–4.

Commentary: left heart remodeling with septal myectomy: fibrosis is a relative but not absolute concern

Blitzer D, Weiner SD, Nguyen SN, Takayama H. J Thorac Cardiovasc Surg 2022;163:1837–8.

Commentary: paradoxical increase in areas of myocardial fibrosis following septal myectomy

Nguyen A. J Thorac Cardiovasc Surg 2022;163:1835.

Hypertrophic cardiomyopathy risk scoring for sudden cardiac death in paediatrics, adolescents, and adults: stuck on the puzzle of clinical, imaging, and genetic features

Bianco F, Bucciarelli V. Eur J Prev Cardiol 2022;29:675–7.

Septal reduction strategies in hypertrophic cardiomyopathy—the scalpel, catheter, or wire?

Bataiosu DR, Rakowski H. JAMA Cardiol 2022;7:538–9.

Surgical septal myectomy and alcohol ablation: not equivalent in efficacy or survival

Sherrid MV, Massera D, Swistel DG. J Am Coll Cardiol 2022;79:1656–9.

Cardiac myosin inhibitors for obstructive hypertrophic cardiomyopathy: where are we on the hype cycle?

Ommen SR. J Am Coll Cardiol 2022;80:109–10.

Hypertrophic cardiomyopathy: a problem at any age

Rossano JW, Lin KY. J Am Coll Cardiol 2022;79:1998–2000.

Beta-blockers and exercise hemodynamics in hypertrophic cardiomyopathy

Borlaug BA, Omote K. J Am Coll Cardiol 2022;79:1576–8.

Targeting the cause of obstructive hypertrophic cardiomyopathy

Larkin HD. JAMA 2022;327:2067.

Future role of new negative inotropic agents in the era of established surgical myectomy for symptomatic obstructive hypertrophic cardiomyopathy

Maron BJ, Maron MS, Sherrid MV, Rowin EJ. J Am Heart Assoc 2022;11:e024566.

Cardiac myosin inhibitors as a novel treatment option for obstructive hypertrophic cardiomyopathy: addressing the core of the matter

Masri A, Olivotto I. J Am Heart Assoc 2022;11:e024656.

Editorial for "left ventricular outflow tract obstruction in hypertrophic cardiomyopathy: the utility of myocardial strain based on cardiac MR tissue tracking"

Boban M. J Magn Reson Imaging 2021;53:552–3.

Ablation of atrial fibrillation in hypertrophic cardiomyopathy: Semper Discere (Always Learning)

Estes NAM 3rd, Wong TC. J Am Heart Assoc 2021;10:e019876.

Role of Imaging in Cardiomyopathies

Cardiac Failure Review 2023;9:e08.

Rare Presentation of Cardiac Sarcoidosis With Recurrent Large Pericardial Effusion and Stress-induced Cardiomyopathy

Journal of Asian Pacific Society of Cardiology 2022;1:e23.

Imaging in Women with Heart Failure: Sex-specific Characteristics and Current Challenges

Cardiac Failure Review 2022;8:e29.

Chest Pain in the Cancer Patient

European Cardiology Review 2022;17:e15.

Advocacy and Legislation for Regionalization Practices in the Treatment of Cardiogenic Shock: The Time Is Now

US Cardiology Review 2022;16:e06.

Extracorporeal Membrane Oxygenation as a Treatment for Branch Pulmonary Artery Rupture Following Right Heart Catheterisation

Cardiac Failure Review 2022;8:e03.

Carbohydrate Antigen 125: A Biomarker at the Crossroads of Congestion and Inflammation in Heart Failure

Cardiac Failure Review 2021;7:e19.

Extracorporeal Life Support for Cardiac Arrest and Cardiogenic Shock

US Cardiology Review 2021;15:e23.

Risk Stratification in Arrhythmogenic Right Ventricular Cardiomyopathy

Arrhythmia & Electrophysiology Review 2021;10(1):26–32.

Novel Aspects of Classification, Prognosis and Therapy in Takotsubo Syndrome

European Cardiology Review 2019;14(3):191–6

Diagnosis and Therapy of Cardiac Sarcoidosis: A Clinical Perspective

US Cardiology Review 2019;13(1):41–5

Diabetic Cardiomyopathy: Five Major Questions with Simple Answers

US Cardiology Review 2019;13(1):46–8

Chagas Disease and Heart Failure: An Expanding Issue Worldwide

European Cardiology Review 2019;14(2):82–8

Hidden in Heart Failure

European Cardiology Review 2019;14(2):89–96

Preventive Ventricular Tachycardia Ablation in Patients with Ischaemic Cardiomyopathy: Meta-analysis of Randomised Trials

Arrhythmia & Electrophysiology Review 2019;8(3):173–9.

Amyloid Heart Disease

US Cardiology Review 2018;12(2):113–8.

Relationship Between VEGF-C Levels and All-cause Mortality in Patients with Chronic Heart Failure

European Cardiology Review 2018;13(2):129.

A PRMT5 Selective Inhibitor EPZ015666 Suppressed TAC-induced Left Ventricular Dysfunction

European Cardiology Review 2018;13(2):130.

Arrhythmogenic Inflammatory Cardiomyopathy: A Review

Arrhythmia & Electrophysiology Review 2018;7(3):181–6.

Fulminant Myocarditis: A Review of the Current Literature

US Cardiology Review 2018;12(1):13–6.